View Future GrowthBee Vectoring Technologies International 過去の業績過去 基準チェック /06Bee Vectoring Technologies Internationalの収益は年間平均-1.2%の割合で減少していますが、 Chemicals業界の収益は年間 増加しています。収益は年間12.4% 19.9%割合で 増加しています。主要情報-1.21%収益成長率13.45%EPS成長率Chemicals 業界の成長4.55%収益成長率19.87%株主資本利益率-863.14%ネット・マージン-4,018.68%前回の決算情報30 Jun 2024最近の業績更新Reported Earnings • Sep 01Third quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.006 loss per share (in line with 3Q 2023). Net loss: CA$1.18m (loss widened 41% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 04Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0.004 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0 (improved from CA$0.004 loss in 2Q 2023). Revenue: CA$81.9k (down 77% from 2Q 2023). Net income: CA$20.9k (up CA$567.2k from 2Q 2023). Profit margin: 26% (up from net loss in 2Q 2023).Reported Earnings • Jan 30Full year 2023 earnings released: CA$0.034 loss per share (vs CA$0.041 loss in FY 2022)Full year 2023 results: CA$0.034 loss per share (improved from CA$0.041 loss in FY 2022). Revenue: CA$601.6k (up 21% from FY 2022). Net loss: CA$4.67m (loss narrowed 5.2% from FY 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 03Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.008 loss in 3Q 2022)Third quarter 2023 results: CA$0.006 loss per share (improved from CA$0.008 loss in 3Q 2022). Revenue: CA$203.2k (up 32% from 3Q 2022). Net loss: CA$836.2k (loss narrowed 9.7% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 02Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0.013 loss in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (improved from CA$0.013 loss in 2Q 2022). Revenue: CA$360.6k (up 26% from 2Q 2022). Net loss: CA$546.3k (loss narrowed 64% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 03First quarter 2023 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 1Q 2022)First quarter 2023 results: CA$0.011 loss per share (further deteriorated from CA$0.009 loss in 1Q 2022). Revenue: CA$44.5k (up 11% from 1Q 2022). Net loss: CA$1.48m (loss widened 37% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesReported Earnings • Sep 01Third quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.006 loss per share (in line with 3Q 2023). Net loss: CA$1.18m (loss widened 41% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.お知らせ • Aug 22Bee Vectoring Technologies International Inc. Receives Mexican Approval on its Proprietary Biological for Commercial UseBee Vectoring Technologies International Inc. announced the Company's proprietary Vectorite with Clonostachys Rosea CR-7 (CR-7) has been approved by Mexico's COFEPRIS (The Federal Commission for Protection from Sanitary Risks), the country's health authority responsible for registration of plant protection products, for use as a fungicide on commercial crops. The approval covers delivery of CR-7 using both bumble bees and honeybees on various high value crops, including the berry group of crops and indoor vegetables. Mexico's growers offer significant market potential for BVT's natural precision agriculture system: official statistics indicate that the country's production in 2019 included 41,600 acres of strawberries, 12,100 acres of blueberries and over 377,000 acres of tomatoes and peppers.(1) In the same year, US imports of fresh and processed fruits and vegetables from Mexico amounted to USD 15.6 billion. The country uses USD 1.3 billion worth of pesticides each year, but an increasing number of growers are turning to biologicals as an alternative that offers better quality, greater food safety and reduces the need for chemicals. Mexico's COFEPRIS registration makes Vectorite with CR-7 available immediately for sale as a registered fungicide for use on the labelled crops.Reported Earnings • Jun 04Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0.004 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0 (improved from CA$0.004 loss in 2Q 2023). Revenue: CA$81.9k (down 77% from 2Q 2023). Net income: CA$20.9k (up CA$567.2k from 2Q 2023). Profit margin: 26% (up from net loss in 2Q 2023).New Risk • Mar 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.4m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Revenue is less than US$1m (CA$574k revenue, or US$423k). Market cap is less than US$10m (CA$7.59m market cap, or US$5.60m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding).お知らせ • Mar 02Bee Vectoring Technologies International Inc., Annual General Meeting, May 10, 2024Bee Vectoring Technologies International Inc., Annual General Meeting, May 10, 2024. Location: Suite 1890 1075 West Georgia Street Vancouver British Columbia CanadaNew Risk • Feb 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Revenue is less than US$1m (CA$602k revenue, or US$446k). Market cap is less than US$10m (CA$5.90m market cap, or US$4.38m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding).お知らせ • Feb 01Bee Vectoring Technologies International Inc. Announces Paid Demonstration Trials in Mexico with Major Multi-National GrowerBee Vectoring Technologies International Inc. announced that a major multi-national grower is conducting demonstration trials in Mexico with BVT's proprietary Vectorite with CR-7 (Clonostachys rosea CR-7) biological fungicide and natural precision agriculture system. This multi-national grower is a key producer of blueberries, raspberries, blackberries and table grapes in Mexico. They have over 5,000 hectares worldwide for the production of berries, with additional operations in the US, Peru and Morocco. After the initial honeybee system trials in their Mexican operations, there is opportunity to expand BVT trials to the other countries. The BVT trials are staggered to the start of bloom time for each berry crop. They commenced last September with the start of blackberry and raspberry bloom periods, moved to blueberry in November, and lasts into early 2024. Trial data is being collected at each crop's harvest time and the grower is currently evaluating for yield performance and percentage of fruit spoilage with BVT and the grower standard applied versus the grower standard used alone. Geographic expansion is a key element in BVT's ongoing corporate expansion strategy. BVT's registration dossier was submitted to regulatory authorities in Mexico in April 2022, and BVT continues to build and expand strategic relationships with Mexican growers. This newest relationship with a multi-national grower with operations in Mexico is a vital step in the Company's continued development in the country.Reported Earnings • Jan 30Full year 2023 earnings released: CA$0.034 loss per share (vs CA$0.041 loss in FY 2022)Full year 2023 results: CA$0.034 loss per share (improved from CA$0.041 loss in FY 2022). Revenue: CA$601.6k (up 21% from FY 2022). Net loss: CA$4.67m (loss narrowed 5.2% from FY 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.お知らせ • Jan 17Bee Vectoring Technologies International Inc. Announces South African Trials with Major Multi-National AgribusinessBee Vectoring Technologies International Inc. announced South African multi-national agricultural technology business Microbial Biological Fertilizers International (MBFi) has commenced trials of BVT products in South Africa. They will be evaluating BVT's patented bee vectoring dispenser for honeybees with proprietary Vectorite powder, initially testing with MBFi's own biological strain as a comparison with traditional spray applications. MBFi manufactures agricultural products for the South African farming industry, supplying fertilizer, biostimulants, biologicals and adjuvants. Trials are being conducted on grower crop fields including macadamias, avocados, apples, strawberries, blueberries and cherries, timed for the start of each crop's bloom period. MBFi will also extend the trials to include sunflowers and canola. In South Africa, macadamia, avocado, applies, strawberries, blueberries and cherry crops cover over 85,000 hectares of farmland, with sunflowers and canola adding another 520,000.New Risk • Sep 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 8.3% per year over the past 5 years. Revenue is less than US$1m (CA$626k revenue, or US$460k). Market cap is less than US$10m (CA$12.1m market cap, or US$8.93m). Minor Risk Shareholders have been diluted in the past year (7.7% increase in shares outstanding).Reported Earnings • Sep 03Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.008 loss in 3Q 2022)Third quarter 2023 results: CA$0.006 loss per share (improved from CA$0.008 loss in 3Q 2022). Revenue: CA$203.2k (up 32% from 3Q 2022). Net loss: CA$836.2k (loss narrowed 9.7% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 02Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0.013 loss in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (improved from CA$0.013 loss in 2Q 2022). Revenue: CA$360.6k (up 26% from 2Q 2022). Net loss: CA$546.3k (loss narrowed 64% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.お知らせ • May 16Bee Vectoring Technologies International Inc. announced that it has received CAD 0.27 million in fundingOn May 15, 2023, Bee Vectoring Technologies International Inc. closed the transaction. All securities issued pursuant to the transaction are subject to a statutory hold period which will expire on September 13, 2023 in accordance with applicable securities laws of Canada.Reported Earnings • Mar 03First quarter 2023 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 1Q 2022)First quarter 2023 results: CA$0.011 loss per share (further deteriorated from CA$0.009 loss in 1Q 2022). Revenue: CA$44.5k (up 11% from 1Q 2022). Net loss: CA$1.48m (loss widened 37% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Jim Molyneux was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 24Bee Vectoring Technologies International Inc. Announces Appointment of Ashish Malik to Its Board of DirectorsBee Vectoring Technologies International Inc. announced the appointment of Ashish Malik to the Company's board of directors. Mr. Malik is currently the Chief Executive Officer and President of BVT. He was previously the VP of Global Marketing for Biologics at Bayer CropScience. He was responsible for managing the portfolio of biological assets for the Company and advancing the strategy to develop integrated crop solutions that include biological products together with traditional chemical products, seeds, traits, seed treatments and services. Mr. Malik joined Bayer CropScience through the Company's acquisition of AgraQuest in 2012. At AgraQuest, he was Senior Vice President of Global Marketing and a member of the Company's Executive Team. Mr. Malik's previous roles have included Head of Commercial Operations for the Home Care Division at Syngenta, Business Unit Director at Imerys and Marketing Manager at BFGoodrich. Mr. Malik serves on the Board of the Biological Products Industry Alliance, holds an MBA with concentrations in Finance and Marketing from Carnegie Mellon University - Tepper School of Business and a bachelor's degree in Engineering from Swarthmore College.お知らせ • Dec 10Bee Vectoring Technologies International Inc. Announces Further Geographic Expansion with Official Submission for Regulatory Approval in CanadaBee Vectoring Technologies International Inc. announced that the company's proprietary Clonostachys rosea CR-7 (CR-7) biological fungicide has been submitted for regulatory review and approval in Canada. The submitted dossier includes CR-7 trial data already successfully completed, as well as studies into human safety, environmental impact, product efficacy and more, as required. For the past two years leading up to the submission, BVT worked with the Health Canada PestManagement Regulatory Agency (PMRA), Canada's agency for pesticide regulation, in pre-submissionconsultations to preemptively and successfully address additional tests that the Company learned wouldbe expected, including efficacy trials, which should mean a more efficient review process. The submission is focused on crops that require pollination by commercially reared and managed bees,such as strawberries, tomatoes, canola, blueberries, sunflowers, cherries and plums.お知らせ • Nov 19Bee Vectoring Technologies International Inc., Annual General Meeting, Jan 19, 2023Bee Vectoring Technologies International Inc., Annual General Meeting, Jan 19, 2023.お知らせ • Oct 07Bee Vectoring Technologies International Inc. Announces Paid Demonstration Trials Secured with Mexican Growers of CR-7 Biological FungicideBee Vectoring Technologies International Inc. announced the first paid demonstration trials of BVT's Clonostachys rosea CR-7 (CR-7) proprietary biological fungicide with two berry growers in Mexico. The trials will gather data on bee vectoring with CR-7 on common fungal diseases including Botrytis (gray mold). Since submitting the registration dossier to Mexican regulatory authorities in April this year, BVT has been establishing strong relationships with Mexican growers. Currently, in addition to the two paid demonstration trials already planned, the team continues to work on securing more trials with farmers in Mexico for the upcoming growing season.お知らせ • Sep 16Bee Vectoring Technologies Reports Up to 33% Yield Increase and 70% Disease Reduction with Leading Georgia Blueberry GrowerBee Vectoring Technologies International Inc. announced positive results with a leading Georgia blueberry grower using BVT's natural precision agriculture system. The 2022 independently collected data from this grower's conventional and organic operations shows that BVT's proprietary VectoriteTM with CR-7 (Clonostachys rosea CR-7) biological fungicide system offered significant advantages over traditional fungicide-only spray programs: 33% higher marketable yield on organic blueberry crop; 12% higher marketable yield on conventional blueberry crop; 70% reduction in Anthracnose disease incidence (organic site); 54% increase in healthy berries postharvest (organic site).お知らせ • Jul 13Bee Vectoring Technologies International Inc. announced that it has received CAD 3.8 million in funding from Sorbie Bornholm LPBee Vectoring Technologies International Inc. announced a non-brokered private placement of units and unsecured convertible notes to Sorbie Bornholm LP for gross proceeds of CAD 3.8 million on July 11, 2022.お知らせ • Apr 01Bee Vectoring Technologies Announces Ongoing 2022 Almond Trials in CaliforniaBee Vectoring Technologies International Inc. announced it is conducting 10 almond trials in the 2022 growing season, which started during the almond bloom period (mid-February to mid-March) and will continue through harvest in the Fall. The locations are throughout California's Central Valley, including in Bakersville, in the Fresno area, and in Northern California. This is the second year for BVT almond trials as farmers require multi-year data under local conditions for proof of efficacy. The California almond market is important to BVT because of its huge market potential, and California almond pollination is believed to be the large single pollination event worldwide. Valued at over USD 6 billion,almonds are California's large non-dairy crop in the state, with over 1.2 million acres in production. Almond growing is big business and the sector has key sustainability objectives: the Almond Board of California has committed to increasing adoption of environmentally-friendly pest management tools by 25% by 2025.Four R&D trials are being conducted to gather further disease and nut rot data, and to determine nutmeal quality. Four grower demonstrations are being used to collect harvest yield and nutmeal quality data to allow farmers to evaluate BVT in stage 1 of the new customer sales adoption cycle. Some of the trials are with large and influential companies in the almond growing community. Across the eight trials, four varieties of almonds are being treated with BVT's proprietary Vectorite with CR-7 (Clonostachys rosea CR-7) biological fungicide, applied with bee vectoring. Two further spray trials are being conducted with the University of California Department of Microbiology and Plant Pathology. This is the second year CR-7 has been included in the research program, spraying it on almond trees at bloom to assess control of brown rot blossom blight (Monilinia laxa) and jacket rot (Botrytis cinerea). BVT's precision agriculture system helps growers meet this goal. The 2022 trials will grow awareness and provide proof of concept that BVT technology controls key fungal pathogens in almonds in a manner consistent with the objectives of the Almond Board. For trials to be useable, the disease has to be present, which isn't the case every year, particularly in dry windy seasons. Several seasons and multiple sites may be required to demonstrate effectiveness for disease control. At minimum, the yield data obtained will be extremely valuable in initiating the salesprocess with almond growers.お知らせ • Feb 10Bee Vectoring Technologies International Inc. Announces the Results of the 2021 Rutgers R&D Trial in New JerseyBee Vectoring Technologies International Inc. announces the results of the 2021 Rutgers R&D trial in New Jersey to assess the efficacy of BVT's proprietary Vectorite with CR-7 (Clonostachys rosea CR-7), applied with bee vectoring technology against blueberry anthracnose (Colletotrichum acutatum), the most damaging disease pathogen in eastern highbush blueberry production. The trial was conducted by Rutgers University's Specialty Crop Research and Extension Center and PE Marucci Blueberry Cranberry Research & Extension Center, a leading and grower-trusted research center in the US Northeast, during the 2021 growing season. The objective of the study was to assess efficacy of the BVT system in controlling the development of disease, and the yield of healthy berries after harvest, both critical measures for how long picked berries remain fresh. Trial results showed BVT's honeybee system and biofungicide had an 8-27% reduction in the disease. The BVT system alone reduced Anthracnose infection in postharvest berries by 27% compared to the control crop (no spray) and 8% compared to the grower standard application. The BVT system alonehad better disease control than the current grower standard. The trial also resulted in 11-60% greater yield of healthy berries at postharvest. When the BVT system was used alone, the trial had 11% more healthy berries 10 days after harvest than a standard program, and 60% more than the control crop, which used no protection products. In both cases, BVT's biological fungicide CR-7 used alone showed higher biological efficacy than the conventional (chemical) fungicide programs. Rutgers University also conducted a grower demonstration on a conventional blueberry farm in NewJersey using the BVT bumblebee system, with even more dramatic results: combining BVT with conventional spray application saw an 84% decrease in anthracnose compared to a spray program alone. Blueberries are a major crop in New Jersey. With 9,000 acres of blueberries, the crop is big business in the state, producing 44 million pounds every year and amounting to USD 62.4 million in annual revenue.Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.036 loss per share (up from CA$0.078 loss in FY 2020). Revenue: CA$399.1k (up 38% from FY 2020). Net loss: CA$4.12m (loss narrowed 39% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.Reported Earnings • Sep 01Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.013 loss in 3Q 2020)Third quarter 2021 results: Net loss: CA$1.13m (loss narrowed 5.0% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.お知らせ • Aug 24Bee Vectoring Technologies International Inc. announced that it has received CAD 6 million in funding from Alumina Partners (Ontario) Ltd.On August 23, 2021, Bee Vectoring Technologies International Inc. closed the transaction.Board Change • Jul 31High number of new directorsIndependent Director Mark Kohler was the last director to join the board, commencing their role in 2021.Recent Insider Transactions • Apr 15Independent Director recently sold CA$74k worth of stockOn the 13th of April, Jim Molyneux sold around 188k shares on-market at roughly CA$0.39 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$281k more than they bought in the last 12 months.お知らせ • Mar 12Bee Vectoring Technologies Announces Start of the Sales Process in the California Almond MarketBee Vectoring Technologies International Inc. announced it has started its first grower trials in the Company's largest single crop opportunity in the US to date, the California almond market. BVT has begun trials with five almond growers and key crop advisors in the main almond growing region in the state, the Central Valley. The five new trials come less than two months of BVT receiving state regulatory approval for its proprietary Vectorite with CR-7 (Clonostachys rosea CR-7) (CR-7) biological fungicide. The Company was not able to conduct field trials before this approval. Securing this level of trials from growers in a new state, in a new crop and in such a short period of time, signifies the momentum that BVT is now achieving in the US market. Like the Company's recent announcement on berry trials with California growers, this speaks to the opportunity for acceleration of BVT's growth in the largest agricultural market in the US. BVT is also in discussions with the Almond Board of California, which represents 7,600 almond growers and 100 handlers. The Almond Board is one of the US's leading crop associations with commitment to increase adoption of environmentally-friendly pest management tools by 25% by 2025. The objective of these first trials is to gain awareness, and proof of concept for the BVT technology to control key fungal pathogens in almonds, in a manner consistent with the objectives of Almond Board. The field trials are now underway in California's Central Valley and are designed to confirm that bees can carry CR-7 to the almond bloom efficiently in order to manage the disease. Four are commercial demonstrations led by agricultural consultants or crop advisors who work directly for growers and are responsible for evaluating and recommending disease and pest control solutions. The fifth is an R&D trial, led by a well-respected researcher with connections to the Almond Board of California, and conducted on 20 acres of a large almond orchard. Following standard scientific protocols, this trial will assess the efficacy of bee vectoring with CR-7 on disease and crop yield, looking at BVT-treated plots, untreated plots and those with and without conventional fungicide sprays. In order for the trials to be useable, the disease has to be present and this is not always the case every year, particularly in dry windy seasons, so several seasons and multiple sites may be required to demonstrate the effectiveness of the BVT system.お知らせ • Feb 05Bee Vectoring Technologies International Inc. announced that it has received CAD 2.33812 million in fundingBee Vectoring Technologies International Inc. (CNSX:BEE) announced a non-brokered private placement of 7,306,625 units at a price of CAD 0.32 per unit for gross aggregate proceeds of CAD 2,338,120 on February 4, 2021. Each unit will consist of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder, on exercise, to purchase one additional share for a period of 24 months following the closing, at an exercise price of CAD 0.525 per share. All securities issued will be subject to a statutory hold period that will expire on June 5, 2021. The company paid finders fees CAD 122,956.40 in cash and 384,238 Warrants exercisable to purchase one additional share per warrant with an exercise price of $0.425 for a period of 2 years from issuance.お知らせ • Feb 02Bee Vectoring Technologies International Inc. Secures California LicenseBee Vectoring Technologies International Inc. announced it has been issued a commercial license from the California Department of Pesticide Regulation (CDPR) on its proprietary Vectorite with CR-7 (Clonostachys rosea CR-7) (CR-7) biological fungicide following completion of the CDPR approval review process last month. BVT's product is now available for sale in California. Previously, the Company had received its US Environmental Protection Agency (EPA) approval in August 2019.Is New 90 Day High Low • Jan 12New 90-day high: CA$0.42The company is up 42% from its price of CA$0.30 on 13 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 26% over the same period.Is New 90 Day High Low • Dec 23New 90-day high: CA$0.39The company is up 28% from its price of CA$0.30 on 23 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 20% over the same period.お知らせ • Dec 19Bee Vectoring Technologies International Inc. announced that it has received CAD 0.266667 million in fundingBee Vectoring Technologies International Inc. (CNSX:BEE) announced a private placement of 1,111,111 units at a price of CAD 0.24 per unit for gross aggregate proceeds of CAD 266,666.64 on December 17, 2020. Each unit consists of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder, on exercise, to purchase one additional share for a period of 24 months following the closing, at an exercise price of CAD 0.40 per share. All securities issued will be subject to a statutory hold period that will expire on April 18, 2021, in accordance with applicable securities laws.Is New 90 Day High Low • Oct 28New 90-day low: CA$0.26The company is down 33% from its price of CA$0.39 on 30 July 2020. The Canadian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.お知らせ • Oct 08Bee Vectoring Technologies International Inc. announced that it has received CAD 0.638728 million in fundingBee Vectoring Technologies International Inc. (TSXV:BEE) announced that is has closed a non-brokered private placement of 2,661,366 units at a price of CAD 0.24 per unit for gross aggregate proceeds of CAD 638,727.84 on October 7, 2020. Each unit consist of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder to purchase one additional share for a period of 24 months following the closing, at an exercise price of CAD 0.40 per share. The 10-day volume weight average price of the shares, as traded on the TSX Venture Exchange, be equal to or greater than a 100% premium to the warrant exercise price prior to the expiry date of the applicable warrants, the company may accelerate the expiry date of the warrants by providing the warrant holders with notice of its election to do so. The accelerated expiry date referenced in an acceleration notice may be no earlier than the 30th day from the date on which such accelerated expiry date is delivered to the warrant holders. All securities issued in the transaction will be subject to a statutory hold period that will expire on February 8, 2021. The company has paid finder’s fees of CAD 1,024.80 cash and issued 4,270 warrants. Finder's warrants has same terms as warrants issued in the transaction.お知らせ • Sep 24Bee Vectoring Technologies International Inc. Successfully Completes Phase 2 Evaluations of Biological Products for In-Licensing and Revenue ExtensionBee Vectoring Technologies International Inc. announced that it has reached another important milestone in its ability to unlock new revenue streams through third-party product in-licensing, having successfully concluded Phase 2 evaluations. Following Phase 1 testing of six products, the Company completed a Phase 2 proof-of-concept field trial with two biological insecticides in North America. Field trials in Europe with a third biological insecticide, in addition to a biological fungicide are in progress and are expected to be completed by late fall. The objective for these initial field trials is to confirm successful delivery of the products to crops of interest through BVT's natural precision agriculture dispensing systems and to assess initial product efficacy. In the North American trial, the biological insecticides were found to be present in the flower tissue following application, confirming that microorganisms were successfully delivered and subsequently colonized the crop through the BVT system. Furthermore, a reduction in the population of crop damaging plant bugs was observed in the crop during the course of the season - establishing the biological efficacy of these systems for managing pest pressure.Is New 90 Day High Low • Sep 22New 90-day low: CA$0.28The company is down 26% from its price of CA$0.38 on 24 June 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.お知らせ • Aug 21Bee Vectoring Technologies International Inc.(TSXV:BEE) dropped from S&P/TSX Venture Composite IndexBee Vectoring Technologies International Inc.(TSXV:BEE) dropped from S&P/TSX Venture Composite Index収支内訳Bee Vectoring Technologies International の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史CNSX:BEE 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費30 Jun 240-52031 Mar 240-42031 Dec 231-53030 Sep 231-53030 Jun 231-43031 Mar 231-44131 Dec 221-54130 Sep 220-54130 Jun 220-54131 Mar 220-54131 Dec 210-43130 Sep 210-43130 Jun 210-54131 Mar 210-54031 Dec 200-54030 Sep 200-75030 Jun 200-54031 Mar 200-54031 Dec 190-54030 Sep 190-32030 Jun 190-32031 Mar 190-32031 Dec 180-32030 Sep 180-32030 Jun 180-32131 Mar 180-32031 Dec 170-32130 Sep 170-32130 Jun 170-32031 Mar 170-32131 Dec 160-32130 Sep 160-32130 Jun 160-32131 Mar 160-42031 Dec 150-42030 Sep 150-31030 Jun 150-21031 Mar 15000031 Dec 140000質の高い収益: BEEは現在利益が出ていません。利益率の向上: BEEは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BEEは利益が出ておらず、過去 5 年間で損失は年間1.2%の割合で増加しています。成長の加速: BEEの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: BEEは利益が出ていないため、過去 1 年間の収益成長をChemicals業界 ( 0.1% ) と比較することは困難です。株主資本利益率高いROE: BEEは現在利益が出ていないため、自己資本利益率 ( -863.14% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/05/04 18:37終値2025/02/04 00:00収益2024/06/30年間収益2023/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bee Vectoring Technologies International Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Sep 01Third quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.006 loss per share (in line with 3Q 2023). Net loss: CA$1.18m (loss widened 41% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 04Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0.004 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0 (improved from CA$0.004 loss in 2Q 2023). Revenue: CA$81.9k (down 77% from 2Q 2023). Net income: CA$20.9k (up CA$567.2k from 2Q 2023). Profit margin: 26% (up from net loss in 2Q 2023).
Reported Earnings • Jan 30Full year 2023 earnings released: CA$0.034 loss per share (vs CA$0.041 loss in FY 2022)Full year 2023 results: CA$0.034 loss per share (improved from CA$0.041 loss in FY 2022). Revenue: CA$601.6k (up 21% from FY 2022). Net loss: CA$4.67m (loss narrowed 5.2% from FY 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 03Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.008 loss in 3Q 2022)Third quarter 2023 results: CA$0.006 loss per share (improved from CA$0.008 loss in 3Q 2022). Revenue: CA$203.2k (up 32% from 3Q 2022). Net loss: CA$836.2k (loss narrowed 9.7% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 02Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0.013 loss in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (improved from CA$0.013 loss in 2Q 2022). Revenue: CA$360.6k (up 26% from 2Q 2022). Net loss: CA$546.3k (loss narrowed 64% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 03First quarter 2023 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 1Q 2022)First quarter 2023 results: CA$0.011 loss per share (further deteriorated from CA$0.009 loss in 1Q 2022). Revenue: CA$44.5k (up 11% from 1Q 2022). Net loss: CA$1.48m (loss widened 37% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 01Third quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.006 loss per share (in line with 3Q 2023). Net loss: CA$1.18m (loss widened 41% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
お知らせ • Aug 22Bee Vectoring Technologies International Inc. Receives Mexican Approval on its Proprietary Biological for Commercial UseBee Vectoring Technologies International Inc. announced the Company's proprietary Vectorite with Clonostachys Rosea CR-7 (CR-7) has been approved by Mexico's COFEPRIS (The Federal Commission for Protection from Sanitary Risks), the country's health authority responsible for registration of plant protection products, for use as a fungicide on commercial crops. The approval covers delivery of CR-7 using both bumble bees and honeybees on various high value crops, including the berry group of crops and indoor vegetables. Mexico's growers offer significant market potential for BVT's natural precision agriculture system: official statistics indicate that the country's production in 2019 included 41,600 acres of strawberries, 12,100 acres of blueberries and over 377,000 acres of tomatoes and peppers.(1) In the same year, US imports of fresh and processed fruits and vegetables from Mexico amounted to USD 15.6 billion. The country uses USD 1.3 billion worth of pesticides each year, but an increasing number of growers are turning to biologicals as an alternative that offers better quality, greater food safety and reduces the need for chemicals. Mexico's COFEPRIS registration makes Vectorite with CR-7 available immediately for sale as a registered fungicide for use on the labelled crops.
Reported Earnings • Jun 04Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0.004 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0 (improved from CA$0.004 loss in 2Q 2023). Revenue: CA$81.9k (down 77% from 2Q 2023). Net income: CA$20.9k (up CA$567.2k from 2Q 2023). Profit margin: 26% (up from net loss in 2Q 2023).
New Risk • Mar 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.4m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Revenue is less than US$1m (CA$574k revenue, or US$423k). Market cap is less than US$10m (CA$7.59m market cap, or US$5.60m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding).
お知らせ • Mar 02Bee Vectoring Technologies International Inc., Annual General Meeting, May 10, 2024Bee Vectoring Technologies International Inc., Annual General Meeting, May 10, 2024. Location: Suite 1890 1075 West Georgia Street Vancouver British Columbia Canada
New Risk • Feb 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Revenue is less than US$1m (CA$602k revenue, or US$446k). Market cap is less than US$10m (CA$5.90m market cap, or US$4.38m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding).
お知らせ • Feb 01Bee Vectoring Technologies International Inc. Announces Paid Demonstration Trials in Mexico with Major Multi-National GrowerBee Vectoring Technologies International Inc. announced that a major multi-national grower is conducting demonstration trials in Mexico with BVT's proprietary Vectorite with CR-7 (Clonostachys rosea CR-7) biological fungicide and natural precision agriculture system. This multi-national grower is a key producer of blueberries, raspberries, blackberries and table grapes in Mexico. They have over 5,000 hectares worldwide for the production of berries, with additional operations in the US, Peru and Morocco. After the initial honeybee system trials in their Mexican operations, there is opportunity to expand BVT trials to the other countries. The BVT trials are staggered to the start of bloom time for each berry crop. They commenced last September with the start of blackberry and raspberry bloom periods, moved to blueberry in November, and lasts into early 2024. Trial data is being collected at each crop's harvest time and the grower is currently evaluating for yield performance and percentage of fruit spoilage with BVT and the grower standard applied versus the grower standard used alone. Geographic expansion is a key element in BVT's ongoing corporate expansion strategy. BVT's registration dossier was submitted to regulatory authorities in Mexico in April 2022, and BVT continues to build and expand strategic relationships with Mexican growers. This newest relationship with a multi-national grower with operations in Mexico is a vital step in the Company's continued development in the country.
Reported Earnings • Jan 30Full year 2023 earnings released: CA$0.034 loss per share (vs CA$0.041 loss in FY 2022)Full year 2023 results: CA$0.034 loss per share (improved from CA$0.041 loss in FY 2022). Revenue: CA$601.6k (up 21% from FY 2022). Net loss: CA$4.67m (loss narrowed 5.2% from FY 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
お知らせ • Jan 17Bee Vectoring Technologies International Inc. Announces South African Trials with Major Multi-National AgribusinessBee Vectoring Technologies International Inc. announced South African multi-national agricultural technology business Microbial Biological Fertilizers International (MBFi) has commenced trials of BVT products in South Africa. They will be evaluating BVT's patented bee vectoring dispenser for honeybees with proprietary Vectorite powder, initially testing with MBFi's own biological strain as a comparison with traditional spray applications. MBFi manufactures agricultural products for the South African farming industry, supplying fertilizer, biostimulants, biologicals and adjuvants. Trials are being conducted on grower crop fields including macadamias, avocados, apples, strawberries, blueberries and cherries, timed for the start of each crop's bloom period. MBFi will also extend the trials to include sunflowers and canola. In South Africa, macadamia, avocado, applies, strawberries, blueberries and cherry crops cover over 85,000 hectares of farmland, with sunflowers and canola adding another 520,000.
New Risk • Sep 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 8.3% per year over the past 5 years. Revenue is less than US$1m (CA$626k revenue, or US$460k). Market cap is less than US$10m (CA$12.1m market cap, or US$8.93m). Minor Risk Shareholders have been diluted in the past year (7.7% increase in shares outstanding).
Reported Earnings • Sep 03Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.008 loss in 3Q 2022)Third quarter 2023 results: CA$0.006 loss per share (improved from CA$0.008 loss in 3Q 2022). Revenue: CA$203.2k (up 32% from 3Q 2022). Net loss: CA$836.2k (loss narrowed 9.7% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 02Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0.013 loss in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (improved from CA$0.013 loss in 2Q 2022). Revenue: CA$360.6k (up 26% from 2Q 2022). Net loss: CA$546.3k (loss narrowed 64% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
お知らせ • May 16Bee Vectoring Technologies International Inc. announced that it has received CAD 0.27 million in fundingOn May 15, 2023, Bee Vectoring Technologies International Inc. closed the transaction. All securities issued pursuant to the transaction are subject to a statutory hold period which will expire on September 13, 2023 in accordance with applicable securities laws of Canada.
Reported Earnings • Mar 03First quarter 2023 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 1Q 2022)First quarter 2023 results: CA$0.011 loss per share (further deteriorated from CA$0.009 loss in 1Q 2022). Revenue: CA$44.5k (up 11% from 1Q 2022). Net loss: CA$1.48m (loss widened 37% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Jim Molyneux was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 24Bee Vectoring Technologies International Inc. Announces Appointment of Ashish Malik to Its Board of DirectorsBee Vectoring Technologies International Inc. announced the appointment of Ashish Malik to the Company's board of directors. Mr. Malik is currently the Chief Executive Officer and President of BVT. He was previously the VP of Global Marketing for Biologics at Bayer CropScience. He was responsible for managing the portfolio of biological assets for the Company and advancing the strategy to develop integrated crop solutions that include biological products together with traditional chemical products, seeds, traits, seed treatments and services. Mr. Malik joined Bayer CropScience through the Company's acquisition of AgraQuest in 2012. At AgraQuest, he was Senior Vice President of Global Marketing and a member of the Company's Executive Team. Mr. Malik's previous roles have included Head of Commercial Operations for the Home Care Division at Syngenta, Business Unit Director at Imerys and Marketing Manager at BFGoodrich. Mr. Malik serves on the Board of the Biological Products Industry Alliance, holds an MBA with concentrations in Finance and Marketing from Carnegie Mellon University - Tepper School of Business and a bachelor's degree in Engineering from Swarthmore College.
お知らせ • Dec 10Bee Vectoring Technologies International Inc. Announces Further Geographic Expansion with Official Submission for Regulatory Approval in CanadaBee Vectoring Technologies International Inc. announced that the company's proprietary Clonostachys rosea CR-7 (CR-7) biological fungicide has been submitted for regulatory review and approval in Canada. The submitted dossier includes CR-7 trial data already successfully completed, as well as studies into human safety, environmental impact, product efficacy and more, as required. For the past two years leading up to the submission, BVT worked with the Health Canada PestManagement Regulatory Agency (PMRA), Canada's agency for pesticide regulation, in pre-submissionconsultations to preemptively and successfully address additional tests that the Company learned wouldbe expected, including efficacy trials, which should mean a more efficient review process. The submission is focused on crops that require pollination by commercially reared and managed bees,such as strawberries, tomatoes, canola, blueberries, sunflowers, cherries and plums.
お知らせ • Nov 19Bee Vectoring Technologies International Inc., Annual General Meeting, Jan 19, 2023Bee Vectoring Technologies International Inc., Annual General Meeting, Jan 19, 2023.
お知らせ • Oct 07Bee Vectoring Technologies International Inc. Announces Paid Demonstration Trials Secured with Mexican Growers of CR-7 Biological FungicideBee Vectoring Technologies International Inc. announced the first paid demonstration trials of BVT's Clonostachys rosea CR-7 (CR-7) proprietary biological fungicide with two berry growers in Mexico. The trials will gather data on bee vectoring with CR-7 on common fungal diseases including Botrytis (gray mold). Since submitting the registration dossier to Mexican regulatory authorities in April this year, BVT has been establishing strong relationships with Mexican growers. Currently, in addition to the two paid demonstration trials already planned, the team continues to work on securing more trials with farmers in Mexico for the upcoming growing season.
お知らせ • Sep 16Bee Vectoring Technologies Reports Up to 33% Yield Increase and 70% Disease Reduction with Leading Georgia Blueberry GrowerBee Vectoring Technologies International Inc. announced positive results with a leading Georgia blueberry grower using BVT's natural precision agriculture system. The 2022 independently collected data from this grower's conventional and organic operations shows that BVT's proprietary VectoriteTM with CR-7 (Clonostachys rosea CR-7) biological fungicide system offered significant advantages over traditional fungicide-only spray programs: 33% higher marketable yield on organic blueberry crop; 12% higher marketable yield on conventional blueberry crop; 70% reduction in Anthracnose disease incidence (organic site); 54% increase in healthy berries postharvest (organic site).
お知らせ • Jul 13Bee Vectoring Technologies International Inc. announced that it has received CAD 3.8 million in funding from Sorbie Bornholm LPBee Vectoring Technologies International Inc. announced a non-brokered private placement of units and unsecured convertible notes to Sorbie Bornholm LP for gross proceeds of CAD 3.8 million on July 11, 2022.
お知らせ • Apr 01Bee Vectoring Technologies Announces Ongoing 2022 Almond Trials in CaliforniaBee Vectoring Technologies International Inc. announced it is conducting 10 almond trials in the 2022 growing season, which started during the almond bloom period (mid-February to mid-March) and will continue through harvest in the Fall. The locations are throughout California's Central Valley, including in Bakersville, in the Fresno area, and in Northern California. This is the second year for BVT almond trials as farmers require multi-year data under local conditions for proof of efficacy. The California almond market is important to BVT because of its huge market potential, and California almond pollination is believed to be the large single pollination event worldwide. Valued at over USD 6 billion,almonds are California's large non-dairy crop in the state, with over 1.2 million acres in production. Almond growing is big business and the sector has key sustainability objectives: the Almond Board of California has committed to increasing adoption of environmentally-friendly pest management tools by 25% by 2025.Four R&D trials are being conducted to gather further disease and nut rot data, and to determine nutmeal quality. Four grower demonstrations are being used to collect harvest yield and nutmeal quality data to allow farmers to evaluate BVT in stage 1 of the new customer sales adoption cycle. Some of the trials are with large and influential companies in the almond growing community. Across the eight trials, four varieties of almonds are being treated with BVT's proprietary Vectorite with CR-7 (Clonostachys rosea CR-7) biological fungicide, applied with bee vectoring. Two further spray trials are being conducted with the University of California Department of Microbiology and Plant Pathology. This is the second year CR-7 has been included in the research program, spraying it on almond trees at bloom to assess control of brown rot blossom blight (Monilinia laxa) and jacket rot (Botrytis cinerea). BVT's precision agriculture system helps growers meet this goal. The 2022 trials will grow awareness and provide proof of concept that BVT technology controls key fungal pathogens in almonds in a manner consistent with the objectives of the Almond Board. For trials to be useable, the disease has to be present, which isn't the case every year, particularly in dry windy seasons. Several seasons and multiple sites may be required to demonstrate effectiveness for disease control. At minimum, the yield data obtained will be extremely valuable in initiating the salesprocess with almond growers.
お知らせ • Feb 10Bee Vectoring Technologies International Inc. Announces the Results of the 2021 Rutgers R&D Trial in New JerseyBee Vectoring Technologies International Inc. announces the results of the 2021 Rutgers R&D trial in New Jersey to assess the efficacy of BVT's proprietary Vectorite with CR-7 (Clonostachys rosea CR-7), applied with bee vectoring technology against blueberry anthracnose (Colletotrichum acutatum), the most damaging disease pathogen in eastern highbush blueberry production. The trial was conducted by Rutgers University's Specialty Crop Research and Extension Center and PE Marucci Blueberry Cranberry Research & Extension Center, a leading and grower-trusted research center in the US Northeast, during the 2021 growing season. The objective of the study was to assess efficacy of the BVT system in controlling the development of disease, and the yield of healthy berries after harvest, both critical measures for how long picked berries remain fresh. Trial results showed BVT's honeybee system and biofungicide had an 8-27% reduction in the disease. The BVT system alone reduced Anthracnose infection in postharvest berries by 27% compared to the control crop (no spray) and 8% compared to the grower standard application. The BVT system alonehad better disease control than the current grower standard. The trial also resulted in 11-60% greater yield of healthy berries at postharvest. When the BVT system was used alone, the trial had 11% more healthy berries 10 days after harvest than a standard program, and 60% more than the control crop, which used no protection products. In both cases, BVT's biological fungicide CR-7 used alone showed higher biological efficacy than the conventional (chemical) fungicide programs. Rutgers University also conducted a grower demonstration on a conventional blueberry farm in NewJersey using the BVT bumblebee system, with even more dramatic results: combining BVT with conventional spray application saw an 84% decrease in anthracnose compared to a spray program alone. Blueberries are a major crop in New Jersey. With 9,000 acres of blueberries, the crop is big business in the state, producing 44 million pounds every year and amounting to USD 62.4 million in annual revenue.
Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.036 loss per share (up from CA$0.078 loss in FY 2020). Revenue: CA$399.1k (up 38% from FY 2020). Net loss: CA$4.12m (loss narrowed 39% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
Reported Earnings • Sep 01Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.013 loss in 3Q 2020)Third quarter 2021 results: Net loss: CA$1.13m (loss narrowed 5.0% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
お知らせ • Aug 24Bee Vectoring Technologies International Inc. announced that it has received CAD 6 million in funding from Alumina Partners (Ontario) Ltd.On August 23, 2021, Bee Vectoring Technologies International Inc. closed the transaction.
Board Change • Jul 31High number of new directorsIndependent Director Mark Kohler was the last director to join the board, commencing their role in 2021.
Recent Insider Transactions • Apr 15Independent Director recently sold CA$74k worth of stockOn the 13th of April, Jim Molyneux sold around 188k shares on-market at roughly CA$0.39 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$281k more than they bought in the last 12 months.
お知らせ • Mar 12Bee Vectoring Technologies Announces Start of the Sales Process in the California Almond MarketBee Vectoring Technologies International Inc. announced it has started its first grower trials in the Company's largest single crop opportunity in the US to date, the California almond market. BVT has begun trials with five almond growers and key crop advisors in the main almond growing region in the state, the Central Valley. The five new trials come less than two months of BVT receiving state regulatory approval for its proprietary Vectorite with CR-7 (Clonostachys rosea CR-7) (CR-7) biological fungicide. The Company was not able to conduct field trials before this approval. Securing this level of trials from growers in a new state, in a new crop and in such a short period of time, signifies the momentum that BVT is now achieving in the US market. Like the Company's recent announcement on berry trials with California growers, this speaks to the opportunity for acceleration of BVT's growth in the largest agricultural market in the US. BVT is also in discussions with the Almond Board of California, which represents 7,600 almond growers and 100 handlers. The Almond Board is one of the US's leading crop associations with commitment to increase adoption of environmentally-friendly pest management tools by 25% by 2025. The objective of these first trials is to gain awareness, and proof of concept for the BVT technology to control key fungal pathogens in almonds, in a manner consistent with the objectives of Almond Board. The field trials are now underway in California's Central Valley and are designed to confirm that bees can carry CR-7 to the almond bloom efficiently in order to manage the disease. Four are commercial demonstrations led by agricultural consultants or crop advisors who work directly for growers and are responsible for evaluating and recommending disease and pest control solutions. The fifth is an R&D trial, led by a well-respected researcher with connections to the Almond Board of California, and conducted on 20 acres of a large almond orchard. Following standard scientific protocols, this trial will assess the efficacy of bee vectoring with CR-7 on disease and crop yield, looking at BVT-treated plots, untreated plots and those with and without conventional fungicide sprays. In order for the trials to be useable, the disease has to be present and this is not always the case every year, particularly in dry windy seasons, so several seasons and multiple sites may be required to demonstrate the effectiveness of the BVT system.
お知らせ • Feb 05Bee Vectoring Technologies International Inc. announced that it has received CAD 2.33812 million in fundingBee Vectoring Technologies International Inc. (CNSX:BEE) announced a non-brokered private placement of 7,306,625 units at a price of CAD 0.32 per unit for gross aggregate proceeds of CAD 2,338,120 on February 4, 2021. Each unit will consist of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder, on exercise, to purchase one additional share for a period of 24 months following the closing, at an exercise price of CAD 0.525 per share. All securities issued will be subject to a statutory hold period that will expire on June 5, 2021. The company paid finders fees CAD 122,956.40 in cash and 384,238 Warrants exercisable to purchase one additional share per warrant with an exercise price of $0.425 for a period of 2 years from issuance.
お知らせ • Feb 02Bee Vectoring Technologies International Inc. Secures California LicenseBee Vectoring Technologies International Inc. announced it has been issued a commercial license from the California Department of Pesticide Regulation (CDPR) on its proprietary Vectorite with CR-7 (Clonostachys rosea CR-7) (CR-7) biological fungicide following completion of the CDPR approval review process last month. BVT's product is now available for sale in California. Previously, the Company had received its US Environmental Protection Agency (EPA) approval in August 2019.
Is New 90 Day High Low • Jan 12New 90-day high: CA$0.42The company is up 42% from its price of CA$0.30 on 13 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 26% over the same period.
Is New 90 Day High Low • Dec 23New 90-day high: CA$0.39The company is up 28% from its price of CA$0.30 on 23 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 20% over the same period.
お知らせ • Dec 19Bee Vectoring Technologies International Inc. announced that it has received CAD 0.266667 million in fundingBee Vectoring Technologies International Inc. (CNSX:BEE) announced a private placement of 1,111,111 units at a price of CAD 0.24 per unit for gross aggregate proceeds of CAD 266,666.64 on December 17, 2020. Each unit consists of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder, on exercise, to purchase one additional share for a period of 24 months following the closing, at an exercise price of CAD 0.40 per share. All securities issued will be subject to a statutory hold period that will expire on April 18, 2021, in accordance with applicable securities laws.
Is New 90 Day High Low • Oct 28New 90-day low: CA$0.26The company is down 33% from its price of CA$0.39 on 30 July 2020. The Canadian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.
お知らせ • Oct 08Bee Vectoring Technologies International Inc. announced that it has received CAD 0.638728 million in fundingBee Vectoring Technologies International Inc. (TSXV:BEE) announced that is has closed a non-brokered private placement of 2,661,366 units at a price of CAD 0.24 per unit for gross aggregate proceeds of CAD 638,727.84 on October 7, 2020. Each unit consist of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder to purchase one additional share for a period of 24 months following the closing, at an exercise price of CAD 0.40 per share. The 10-day volume weight average price of the shares, as traded on the TSX Venture Exchange, be equal to or greater than a 100% premium to the warrant exercise price prior to the expiry date of the applicable warrants, the company may accelerate the expiry date of the warrants by providing the warrant holders with notice of its election to do so. The accelerated expiry date referenced in an acceleration notice may be no earlier than the 30th day from the date on which such accelerated expiry date is delivered to the warrant holders. All securities issued in the transaction will be subject to a statutory hold period that will expire on February 8, 2021. The company has paid finder’s fees of CAD 1,024.80 cash and issued 4,270 warrants. Finder's warrants has same terms as warrants issued in the transaction.
お知らせ • Sep 24Bee Vectoring Technologies International Inc. Successfully Completes Phase 2 Evaluations of Biological Products for In-Licensing and Revenue ExtensionBee Vectoring Technologies International Inc. announced that it has reached another important milestone in its ability to unlock new revenue streams through third-party product in-licensing, having successfully concluded Phase 2 evaluations. Following Phase 1 testing of six products, the Company completed a Phase 2 proof-of-concept field trial with two biological insecticides in North America. Field trials in Europe with a third biological insecticide, in addition to a biological fungicide are in progress and are expected to be completed by late fall. The objective for these initial field trials is to confirm successful delivery of the products to crops of interest through BVT's natural precision agriculture dispensing systems and to assess initial product efficacy. In the North American trial, the biological insecticides were found to be present in the flower tissue following application, confirming that microorganisms were successfully delivered and subsequently colonized the crop through the BVT system. Furthermore, a reduction in the population of crop damaging plant bugs was observed in the crop during the course of the season - establishing the biological efficacy of these systems for managing pest pressure.
Is New 90 Day High Low • Sep 22New 90-day low: CA$0.28The company is down 26% from its price of CA$0.38 on 24 June 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.
お知らせ • Aug 21Bee Vectoring Technologies International Inc.(TSXV:BEE) dropped from S&P/TSX Venture Composite IndexBee Vectoring Technologies International Inc.(TSXV:BEE) dropped from S&P/TSX Venture Composite Index